Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan.

Journal of managed care pharmacy : JMCP

Volumn 9, Issue 4, 2003, Pages 327-334

  Shaw, Elizabeth ^a   Stacy, Jane ^a   Arledge, Michele D ^a   Howell Smith, Donna ^a  

^a HUMANA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; CHEMICALLY INDUCED DISORDER; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; PEPTIC ULCER; PHARMACOECONOMICS; PROBABILITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE INHIBITORS; ECONOMICS, PHARMACEUTICAL; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; PEPTIC ULCER; PREFERRED PROVIDER ORGANIZATIONS; PROBABILITY;

MLCS; MLOWN;

EID: 0642347680     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2003.9.4.327     Document Type: Article

References (0)